How Will WebMD Health (WBMD) Stock Respond In After-Market Trading?

NEW YORK (TheStreet) -- WebMD Health (WBMD) shares are down slightly, -0.09% to $4.05, in after-market trading following the release of the company's first quarter earnings report on Wednesday.

The company posted revenue of $133.8 million, a year over year quarterly increase of 19%, beating analysts consensus estimates of $132.36 million.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. 

The company posted net income of 6.3 million, or 15 cents per diluted share in the quarter, beating analysts estimates by 4 cents.

The company also raised the lower end of its previous full year guidance ranges for revenue, $137 million to $140 million, EBITDA, $35.5 million to $35.7 million, and net income, $7.5 million to $8.5 million.

TheStreet Ratings team rates WEBMD HEALTH CORP as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate WEBMD HEALTH CORP (WBMD) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • WEBMD HEALTH CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, WEBMD HEALTH CORP turned its bottom line around by earning $0.33 versus -$0.44 in the prior year. This year, the market expects an improvement in earnings ($0.82 versus $0.33).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Internet Software & Services industry. The net income increased by 277.6% when compared to the same quarter one year prior, rising from -$6.09 million to $10.81 million.
  • The gross profit margin for WEBMD HEALTH CORP is rather high; currently it is at 60.51%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, WBMD's net profit margin of 7.39% significantly trails the industry average.
  • The debt-to-equity ratio is very high at 4.99 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 5.92, which shows the ability to cover short-term cash needs.
  • Net operating cash flow has decreased to $24.18 million or 20.33% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • You can view the full analysis from the report here: WBMD Ratings Report
STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.


WATCH: More market update videos on TheStreet TV | More videos from Kori Hale

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)